Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Breast 1

Conditions

Sarcoma, Endometrial Stromal 1Perivascular Epithelioid Cell Neoplasms 1Adenosarcoma of the uterus 1

Interventions

Cyclophosphamide 93Doxorubicin 92Radiotherapy 87Temozolomide 69Filgrastim 58Ifosfamide 55Bevacizumab 55Etoposide 48Gemcitabine 44Imatinib Mesylate 43Vincristine 40pembrolizumab 35pazopanib 34Peripheral Blood Stem Cell Transplantation 31Methotrexate 31Nivolumab 30Carboplatin 30fludarabine phosphate 29Irinotecan 29Cisplatin 28Paclitaxel 26Melphalan 26Magnetic Resonance Spectroscopy 26Docetaxel 25Busulfan 25Trabectedin 24apatinib 22Specimen Handling 21Sirolimus 21Antilymphocyte Serum 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × RAD1901 × Sarcoma × Clear all
NCT07467772 2026-05-22

Ph 2 Elacestrant in ER Positive Uterine Sarcomas

Dana-Farber Cancer Institute

Phase 2 Recruiting
30 enrolled
GynecologicSarcoma

Adenosarcoma of the uterus, Sarcoma, Endometrial Stromal, Perivascular Epithelioid Cell Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡